Bovie Medical (NYSE:BVX) said this week it inked a sales channel partnership agreement with Arteriocyte Medical Systems to sell Bovie’s J-Plasma to its network of plastic surgeons. Through the deal, Arteriocyte will offer J-Plasma through its U.S. sales network, which Clearwater, Fla.-based Bovie said will significantly expand its use in office-based practices. “We are delighted to sign […]
The nod means the cobalt-chromium stent is "available in all of the major markets worldwide," according to a press releaase, including the U.S., Europe, China and India.
Stem cell developer Arteriocyte has received approval from the Food & Drug Administration to begin a Phase 1 clinical trial for the treatment of critical limb ischemia.
The trial will investigate the use of Arteriocyte’s Magellan technology to improve blood flow in patients suffering from critical limb ischemia (CLI), a severe obstruction of the arteries that reduces blood flow to hands, feet or legs, according to the Cleveland-based company. Serious cases can lead to amputation.
Arteriocyte Inc. launched a stem cell-based product that allows researchers to grow red blood cells outside the human body.
The product, called NANEX, is available only for research use and has not been tested in humans. NANEX is engineered to essentially behave like bone marrow.
“This product is the first internally developed product that Arteriocyte has placed on the market to date,” said Adam Sorkin, a company spokesman. “And it was developed at Arteriocyte’s Cleveland R&D center.”